Small scale clinical trials demonstrate that treatment of TUDCA might have an effect on improving the liver and muscle insulin sensitivity by modulating ER stress (138) and oral 4-PBA treatment provides benefits by alleviating the lipid-induced insulin resistance and β-cell dysfunction caused by ER stress in humans (139). This evidence concerns the gene INS and Insulin resistance.